Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7719282rdf:typepubmed:Citationlld:pubmed
pubmed-article:7719282lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0033809lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0021753lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0027950lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0031990lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0038836lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0008019lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:7719282lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:7719282pubmed:issue2lld:pubmed
pubmed-article:7719282pubmed:dateCreated1995-5-25lld:pubmed
pubmed-article:7719282pubmed:abstractTextWhereas addition of 200 ng ml-1 exotoxin A (exoA) did not modify PMNL chemotaxis, 20 U ml-1 human recombinant interleukin-1 beta (hrIL-1 beta) primed polymorphonuclear leukocytes (PMNL) for migration towards Pseudomonas aeruginosa peptide chemotactins (PAPCs). Piroxicam (100 micrograms ml-1), a non-steroidal anti-inflammatory agent (NSAIA), inhibited PMNL chemotaxis and abolished the priming effect of hrIL-1 beta. Both PAPCs and exoA induced PMNL superoxide anion production, but neither hrIL-1 beta nor piroxicam modified significantly PMNL superoxide anion production induced by PAPCs. The fact that hrIL-1 beta can prime PMNL for chemotaxis towards PAPCs and that piroxicam can abolish activation by primed PMNL are findings relevant to the pharmacological control of lung tissue damage during P. aeruginosa pneumonia.lld:pubmed
pubmed-article:7719282pubmed:languageenglld:pubmed
pubmed-article:7719282pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:citationSubsetIMlld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7719282pubmed:statusMEDLINElld:pubmed
pubmed-article:7719282pubmed:monthJanlld:pubmed
pubmed-article:7719282pubmed:issn0928-8244lld:pubmed
pubmed-article:7719282pubmed:authorpubmed-author:SordelliD ODOlld:pubmed
pubmed-article:7719282pubmed:authorpubmed-author:FontánP APAlld:pubmed
pubmed-article:7719282pubmed:authorpubmed-author:AmuraC RCRlld:pubmed
pubmed-article:7719282pubmed:authorpubmed-author:BuzzolaF RFRlld:pubmed
pubmed-article:7719282pubmed:issnTypePrintlld:pubmed
pubmed-article:7719282pubmed:volume10lld:pubmed
pubmed-article:7719282pubmed:ownerNLMlld:pubmed
pubmed-article:7719282pubmed:authorsCompleteYlld:pubmed
pubmed-article:7719282pubmed:pagination139-44lld:pubmed
pubmed-article:7719282pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:meshHeadingpubmed-meshheading:7719282-...lld:pubmed
pubmed-article:7719282pubmed:year1995lld:pubmed
pubmed-article:7719282pubmed:articleTitleModulation of human polymorphonuclear leukocyte chemotaxis and superoxide anion production by Pseudomonas aeruginosa exoproducts, IL-1 beta and piroxicam.lld:pubmed
pubmed-article:7719282pubmed:affiliationDepartamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Argentina.lld:pubmed
pubmed-article:7719282pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7719282pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7719282lld:pubmed